Table 13, [Quantitative syntheses of HDL-c data,...]. - Comparative Effectiveness of Lipid-Modifying Agents

Warning: The NCBI web site requires JavaScript to function. more...

Quantitative syntheses of HDL-c data, for ezetimibe plus statin combination therapy compared with statin monotherapy

	Number of trials reporting outcome	Number of participants in relevant treatment groups	Point estimate	Lower CI	Upper CI
Difference in mean HDL-c percentage change from baseline (%)
All trials⁴²^,^46–48^,¹⁰⁹^,¹¹⁰^,¹¹²^,^114–118^,¹²¹^,¹²⁴^,¹²⁶^,¹²⁷^,¹²⁹^,¹³⁰^,¹³⁹^,¹⁴⁰^,¹⁴²^,¹⁴⁴^,¹⁵⁴^,¹⁵⁶^,¹⁵⁸^,¹⁵⁹^,^166–169^,¹⁹³^,¹⁹⁴	32	18143	-	-	-
Simvastatin
Lower dose statin in combination therapy versus higher dose monotherapy – all participants⁴⁸^,¹²¹^,¹³⁰^,¹⁵⁴^,¹⁶⁹	5	1585	0.31	−0.89	1.52
Atorvastatin
Lower dose statin in combination therapy versus higher dose monotherapy – moderately high risk¹⁵⁸	1	184	2.40	1.97	2.83
Participants requiring intensive lipid lowering therapy⁴²^,⁴⁷^,¹¹²^,^114–116^,¹¹⁸^,¹²¹^,¹⁴⁰^,¹⁴²^,¹⁴⁴^,¹⁵⁹^,¹⁶⁷^,¹⁹³^,¹⁹⁴	15	7020	1.53	0.81	2.24
Simvastatin
Lower dose statin in combination therapy versus higher dose monotherapy Participants requiring intensive lipid lowering therapy (diabetes mellitus)¹²¹	1	210	−0.10	−3.42	3.22
Participants with LDL-c>190 mg/dL⁴²	1	720	2.40	−0.23	5.03
Participants with diabetes mellitus¹¹⁸^,¹²¹^,¹⁴⁴^,¹⁶⁷^,¹⁹³^,¹⁹⁴	6	2790	-	-	-
Participants with vascular disease¹¹⁴^,¹¹⁶^,¹⁴⁰	3	924	0.04	−1.63	1.72
All participants of African origin¹¹⁷	1	267	3.30	0.35	6.25
All participants of Hispanic origin¹¹⁷	1	147	0.30	−3.64	4.24

: Abbreviations: CI = 95% confidence interval, HDL-c = high density lipoprotein cholesterol, LDL-c = low density lipoprotein cholesterol

Comparative Effectiveness of Lipid-Modifying Agents [Internet].

Comparative Effectiveness Reviews, No. 16.

Sharma M, Ansari MT, Soares-Weiser K, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.